Currently, the FDA-approved thrombolytic therapy of recombinant tissue plasminogen activator (rt-PA) is available for only a small percentage of stroke patients, due to its narrow therapeutic time window of 4.5 hours after stroke onset [2]. This evidence concerns the gene PLAT and stroke disorder.